TMS

About:

A Tokyo-based clinical-stage biotech company. Lead program TMS-007 (acute ischemic stroke) is partnered with Biogen.

Website: http://www.tms-japan.co.jp/en/index.html

Top Investors: Mitsubishi UFJ Capital, MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC), Nissay Capital, Tohoku University Venture Partners, KSP

Description:

TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.